Although high SHIP2 expression has been found in breast cancer, hepatocellular cancer, non-small cell lung cancer, and colorectal cancer, and correlates with poor survival of patients [9,10,11,12], the reduced expression of SHIP2 and its tumor suppressive role in GC has also been reported [4]. Here, INPPL1 is linked to breast carcinoma.